Revolution Medicines (RVMD) Stock Jumps as FDA Approves Its Pancreatic Cancer Pill Early

TLDR

• The FDA approved Revolution Medicines’ drug Rasonque (daraxonrasib) for metastatic pancreatic adenocarcinoma on August 26, 2026
• The approval came months ahead of schedule, following Breakthrough Therapy, Orphan Drug, and priority review designations
• Phase 3 trial data showed patients on Rasonque lived a median of 13.2 months vs. 6.7 months on chemotherapy
• RVMD stock is up over 165% year-to-date; Wall Street has a Strong Buy consensus with an average price target of $222.89
• Around 67,000 Americans are diagnosed with pancreatic cancer each year, with 90-95% having the adenocarcinoma form

Revolution Medicines stock (RVMD) ticked higher on Wednesday after the FDA approved its once-daily pill Rasonque for the treatment of metastatic pancreatic adenocarcinoma. The stock rose around 1% in early trading, though it gave back some of those gains later in the session.

Revolution Medicines, Inc., RVMD

RVMD is already up over 165% year-to-date coming into today, making this approval the latest milestone in what has been a strong run for the biotech.

… Continue reading the full article at the original source below.